CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling
The Journal of Immunology · 01.04.2024 · 212 (7) · 1221-1231
DOI: 10.4049/jimmunol.2300285 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 09.02.2024. Verfasst von Hyogo Naoi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. Hauptthemen laut MEDLINE: Pulmonary Fibrosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS), HUSM grant-in-aid from Hamamatsu University School of Medicine, Boehringer Ingelheim life science research support program.
Abstract (Originalsprache)
Pulmonary fibrosis is a fatal condition characterized by fibroblast and myofibroblast proliferation and collagen deposition. TGF-β plays a pivotal role in the development of pulmonary fibrosis. Therefore, modulation of TGF-β signaling is a promising therapeutic strategy for treating pulmonary fibrosis. To date, however, interventions targeting TGF-β have not shown consistent efficacy. CD109 is a GPI-anchored glycoprotein that binds to TGF-β receptor I and negatively regulates TGF-β signaling. However, no studies have examined the role and therapeutic potential of CD109 in pulmonary fibrosis. The purpose of this study was to determine the role and therapeutic value of CD109 in bleomycin-induced pulmonary fibrosis. CD109-transgenic mice overexpressing CD109 exhibited significantly attenuated pulmonary fibrosis, preserved lung function, and reduced lung fibroblasts and myofibroblasts compared with wild-type (WT) mice. CD109−/− mice exhibited pulmonary fibrosis comparable to WT mice. CD109 expression was induced in variety types of cells, including lung fibroblasts and macrophages, upon bleomycin exposure. Recombinant CD109 protein inhibited TGF-β signaling and significantly decreased ACTA2 expression in human fetal lung fibroblast cells in vitro. Administration of recombinant CD109 protein markedly reduced pulmonary fibrosis in bleomycin-treated WT mice in vivo. Our results suggest that CD109 is not essential for the development of pulmonary fibrosis, but excess CD109 protein can inhibit pulmonary fibrosis development, possibly through suppression of TGF-β signaling. CD109 is a novel therapeutic candidate for treating pulmonary fibrosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Advanced Research Facilities and Services, Hamamatsu University School of Medicine, Hamamatsu, Japan.
- Department of Pathology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
- Department of Biomedical Science, Chubu University Graduate School of Life and Health Science, Kasugai, Japan.
- International Center for Cell and Gene Therapy, Fujita Health University, Toyoake, Japan.
ORCID-Profile: Yuzo Suzuki, Ryo Horiguchi, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Tomoyuki Fujisawa, Naoki Inui, Shinji Mii, Masatoshi Ichihara, Masahide Takahashi, Takafumi Suda
Förderung
- MEXT | Japan Society for the Promotion of Science (JSPS)
- HUSM grant-in-aid from Hamamatsu University School of Medicine
- Boehringer Ingelheim life science research support program
- Boehringer Ingelheim Research Support Program from Japan Respiratory Society
Zitieren
APA
Naoi, H., Suzuki, Y., Miyagi, A., Horiguchi, R., Aono, Y., Inoue, Y., Yasui, H., Hozumi, H., Karayama, M., Furuhashi, K., Enomoto, N., Fujisawa, T., Inui, N., Mii, S., Ichihara, M., Takahashi, M., & Suda, T. (2024). CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling. The Journal of Immunology, 212(7), 1221-1231. https://doi.org/10.4049/jimmunol.2300285
Vancouver
Naoi H, Suzuki Y, Miyagi A, Horiguchi R, Aono Y, Inoue Y, et al. CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling. The Journal of Immunology. 2024;212(7):1221-1231. doi:10.4049/jimmunol.2300285
BibTeX
@article{Naoi2024,
author = {Naoi, Hyogo and Suzuki, Yuzo and Miyagi, Asuka and Horiguchi, Ryo and Aono, Yuya and Inoue, Yusuke and Yasui, Hideki and Hozumi, Hironao and Karayama, Masato and Furuhashi, Kazuki and Enomoto, Noriyuki and Fujisawa, Tomoyuki and Inui, Naoki and Mii, Shinji and Ichihara, Masatoshi and Takahashi, Masahide and Suda, Takafumi},
title = {CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling},
journal = {The Journal of Immunology},
year = {2024},
volume = {212},
number = {7},
pages = {1221--1231},
doi = {10.4049/jimmunol.2300285}
}
EUVIMED